Compendium of Funding Opportunities for TB Research

Prepared by the Global TB Programme

In support of the “Research & Innovation” pillar of the End TB Strategy

November 2016
Acknowledgement

We thank all the TB R&D funders and individuals who supported and contributed to this document, particularly Drs. Christine Sizemore and Alison Kraigsley from the National Institutes of Health/ National Institute of Allergy and Infectious Diseases, USA, for their exceptional support to the design and optimization of the data collection tool, and Mike Frick from the Treatment Action Group for his assistance with the survey.
# Table of Contents

Introduction .......................................................................................................................... i  
Bill and Melinda Gates Foundation ...................................................................................... 1  
Department for International Development, United Kingdom ............................................ 3  
Eunice Kennedy Shriver National Institute of Child Health and Human (NICHD) ...... 4  
European Commission ....................................................................................................... 5  
European & Developing Countries Clinical Trials Partnership (EDCTP) ......................... 7  
Fogarty International Center (FIC) .................................................................................... 9  
German Federal Ministry for Education and Research (BMBF) ........................................ 10  
German Research Foundation (Deutsche Forschungsgemeinschaft, DFG) ..................... 12  
National Cancer Institute (NCI) ....................................................................................... 13  
National Heart, Lung and Blood Institute (NHLBI) ......................................................... 15  
Health Research Board .................................................................................................... 16  
National Health Research Institute, Taiwan ..................................................................... 18  
National Institute of Allergy and Infectious Diseases (NIAID) ........................................ 19  
Research Foundation Flanders (FWO) ............................................................................. 21  
Swedish Research Council ................................................................................................. 23  
The Netherlands Organisation for Health Research and Development (ZonMw) ...... 24  
Thrasher Research Fund .................................................................................................... 25  
United States Agency for International Development (USAID) .................................. 26  
Wellcome Trust ................................................................................................................. 27
Introduction

In line with achieving the goals and targets of the Sustainable Development Goals (SDGs), the World Health Organization (WHO) has developed the END TB Strategy\(^1\), which aims to reduce TB deaths by 90% and to cut new cases by 80% between 2015 and 2030, and to ensure that no family is burdened with catastrophic expenses due to TB. “Intensified research and innovation” has been identified as one of the three essential pillars to end the global TB epidemic.

Identifying funding sources is indispensable to develop and implement TB research projects that aim to develop new technologies and tools to End TB, as well as to optimize the implementation of existing tools, as outlined in WHO’s Global Action Framework for TB Research\(^2\) and the International Roadmap for TB Research\(^3\).

In this context, it is essential that relevant information on funding opportunities is made available and accessible, particularly to researchers in high and medium TB burden countries. While general information about the respective biomedical and clinical funding agencies exist in the public domain, a critical component of accessing funds is the ability to make sense of the respective nuances and areas of interest of the various funders. For example, not every organization has specific calls for TB but may have more generic calls for proposals or general open invitations that can also apply to TB but are not utilized by the community; or funders may be interested in funding only some aspects or areas of research.

Since individual funding organizations follow internal processes and rules for proposal acceptance, review and funding, investigators need to be knowledgeable about these differences to recognize how best to leverage research support for their projects and how to strategically target relevant aspects of research projects to the most appropriate funding organizations and funding opportunities. This is particularly important for cross-cutting projects that span multiple sectors that are not within the mission and resources of one particular funding agency.

The purpose of this document is to help guide investigators in properly approaching existing funding sources/product development resources to structure large scale, or cross-cutting research projects in TB research. To actualize this, the WHO Global TB Programme (GTB) has taken the task of developing a compendium of TB research funding institutions describing key characteristics and information about funding opportunities across different research fields in TB, using a template initially piloted with

---

the assistance of organizations among the top ten funders of global TB Research and Development (as ranked in the 2015 Treatment Action Group report)\textsuperscript{4}.

Responses of TB research funders that completed the compendium template are reported in this document alphabetically. It is expected that this document will be updated periodically to expand on the number of funders contributing to the compendium, and adapt time-sensitive information as appropriate. In addition to researchers, we hope this document will also help inform other stakeholders, including other funders, about various funding and product development resources available to support research projects in TB. It is the first attempt to optimize information on available research funding for both funders and the TB research community at large, especially researchers in high TB burden countries, by creating an improved understanding of the mission, strategy and application mechanisms of main TB research funders.

Bill and Melinda Gates Foundation

**Website** gatesfoundation.org

**Contact** Becky Bartlein, Program Manager, becky.bartlein@gatesfoundation.org

**Funding mission statement** The Global Health Program at the Bill and Melinda Gates Foundation focuses on funding the areas of greatest need where we can have the greatest impact.

**Potential awardees**
- Academia
- Public sector
- Private sector
- Public private partnerships
- NGOs
- Pharmaceutical industries

**Funding information**
- Web link to general public funding opportunities
  http://www.gatesfoundation.org/How-We-Work/General-Information/Grant-Opportunities
- Web link to previously/currently funded projects
  http://www.gatesfoundation.org/How-We-Work/Quick-Links/Grants-Database

**Research areas supported**
- Basic research
- Translational research
- Product development
- Pre-clinical services
- Pre-clinical development
- Clinical trials
- Epidemiology
- Operational research

**Funder distinctions/nuances**
- BMGF funds projects and organizations;
- The TB strategy team does not accept unsolicited grant applications;
- Co-funding of applications is generally not required with some exceptions;
- Domestic and foreign individuals/organizations can apply as described above;
- Funding is generally not geography specific. But for TB related operational research, our focus countries are: China, India and South Africa;
- BMGF does not have specific training grants, but there may be conference support or support for new investigators within grants to support activities that align with existing funding strategy;
- BMGF provides resources for product development.
• BMGF’s funding strategy is elaborated here:
  o http://www.gatesfoundation.org/What-We-Do/Global Health/Tuberculosis#OurStrategy
  o http://www.gatesfoundation.org/How-We-Work/General-Information/Grantseeker-FAQ
• TB strategy is broken into 5 initiatives: vaccines, drugs, diagnostics, delivery, and global resource mobilization & utilization
• While the TB team does not accept unsolicited LOIs, TB related projects can be submitted to the Grand Challenges scheme: http://www.grandchallenges.org/GrantOpportunities/Pages/default.aspx
**Department for International Development, United Kingdom**

**Website**  www.gov.uk/dfid  
**Contact**  Sue Kinn  
**Funding mission statement** The Department for International Development (DFID) leads the UK’s work to end extreme poverty.

**Potential awardees**  
Academia  
Public sector  
Private sector  
Public private partnerships  
NGOs  
Pharmaceutical industries

**Funding basics**  
- Web link to general public funding opportunities  
  http://r4d.dfid.gov.uk/  
- Web link to previously/currently Funded Projects  
  http://r4d.dfid.gov.uk/

**Research areas supported**  
Translational research  
Product development  
Pre-clinical development  
Clinical trials  
Epidemiology  
Operational research  
Research training  
Health systems strengthening research

**Funder distinctions/nuances**  
- DFID funds projects only;  
- Application for funding is through calls only;  
- Co-funding is not required to apply for grants;  
- Only domestic (UK) individuals/organizations may apply but under untied aid, anyone can apply;  
- Although there are no geographic limitations for application and funding, the research must have a focus on poverty alleviation of the very poorest people in low and middle income countries;  
- Resources for training may be available within funding envelopes, but not directly;  
- DFID provides resources for product development.
Eunice Kennedy Shriver National Institute of Child Health and Human (NICHD)

Website www.nichd.nih.gov
Contact www.nichd.nih.gov/about/org/der/branches/mpi/Pages/overview.aspx

Funding mission statement  The Maternal and Pediatric Infectious Disease Branch (MPIDB) of NICHD supports and conducts domestic and international research related to the epidemiology, diagnosis, clinical manifestations, pathogenesis, transmission, treatment, and prevention, and complications of HIV, its associated co-infections, and other priority infectious diseases affecting infants, children, adolescents, and women (pregnant and non-pregnant).

Potential awardees (within and outside of the U.S)
- Academia
- Industry
- Public private partnerships

Funding basics
- Web link to general public funding opportunities
  http://www.nichd.nih.gov/grants-funding/opportunities-mechanisms/active-foa/Pages/default.aspx
- Web link to previously/currently Funded Projects
  http://projectreporter.nih.gov/

Research areas supported
- Translational research
- Clinical trials
- Epidemiology
- Operational research
- Human capital (capacity building)

Funder distinctions/nuances
- NICHD provides funding for specific projects to organizations, training grants are issued to individuals;
- NICHD accepts solicited and unsolicited applications;
- NICHD supports research in populations central to NICHD’s mission: infants, children, adolescents, and women (pregnant and non-pregnant);
- NICHD does not require co-funding of research projects.
European Commission

Website  http://ec.europa.eu/programmes/horizon2020/en
Contact  Dr. Hannu Laang, Hannu.laang@ec.europa.eu

Funding mission statement  Horizon2020 is the biggest European Union (EU) research and innovation program ever with nearly €80 billion of funding available over 7 years. It promises more breakthroughs, discoveries and world-firsts, by taking great ideas from the lab to the market.

Potential awardees
   Academia
   Public sector
   Private sector
   Public private partnerships
   NGOs
   Pharmaceutical industries

Funding basics
   • Web link to general public funding opportunities
   • Web link to previously/currently funded projects

Research areas supported
   Basic research
   Translational research
   Product development
   Pre-clinical development
   Clinical trials
   Epidemiology
   Operational research
   Research training

Mechanisms to support collaborative projects
The programme societal challenges funds large-scale collaborative projects. In the annual work programme there are calls for proposals in topics that have a funding budget between 3 and 30 million euros. In practice, the number of partners in the consortium can be anything between 3 and 50. The aim is to enhance international collaboration and networking. 2014 work programme had a topic on TB vaccine development with the budget of up to 25 million euros for the project.

Funder distinctions/nuances
   • Horizon2020 is divided into three sections: excellent science, industrial leadership and societal challenges. TB research can be supported from each
section, but TB is specifically mentioned as one of the priority areas of research in the Health/Demographic change and wellbeing part of the societal challenges programme. That is the only programme where one can see specific calls in TB. To better understand the EU research programs or to find the right call, please visit the Horizon2020 web page.

- European Commission funds both individuals and/or organizations. European Research Council and Marie Sklodowska-Curie actions fund individual researchers whereas societal challenges funds consortia with at least 3 participants from 3 different EU countries or associated countries;
- Unsolicited proposals are not accepted. TB specific calls do exist in the societal challenges programme, but call topics are usually quite broad without any specific diseases being targeted;
- Co-funding of applications is not required but useful;
- Horizon2020 is a global programme and there is no geographic limitation to funding applications. However, there may be some restrictions for funding for high- and middle-income countries outside of Europe. US-based entities can also get funding;
- The societal challenges programme within Horizon2020 aims at product development.
European & Developing Countries Clinical Trials Partnership (EDCTP)

Website  www.edctp.org
Contact  Dr Ole Olesen (Olesen@edctp.org)

Funding mission statement  Contribute to the reduction of poverty-related diseases in developing countries, in particular in sub-Saharan Africa, by accelerating the clinical development of effective, safe, accessible, suitable and affordable medical interventions in partnership with sub-Saharan Africa.

Potential awardees
Private sector

Funding basics
• Web link to general public funding opportunities
• Web link to previously/currently funded projects
  http://www.edctp.org/our-work/project-profiles/

Research areas supported
  Translational research
  Product development
  Clinical trials
  Epidemiology
  Operational research
  Research training

Mechanisms to support collaborative projects
EDCTP provides support to large-scale collaborative projects, involving research teams from several countries. The core activity is support to phase II and III clinical trials in sub-Saharan Africa. This is done through Integrated Activities, which are large grants (up to 15 million EUR) to consortia of research teams that must involve at least two European and one sub-Saharan African research team.

Funder distinctions/nuances
• EDCTP funds both investigators and/or projects;
• Grant applications are only through calls for proposals;
• Co-funding may be required for some types of grants;
• Only legal entities from countries of the European Union, countries associated to the EU Framework programme (Horizon2020) and countries in sub-Saharan Africa can receive funding;
• Funding is limited to projects in sub-Saharan Africa;
• Allocation of resources to training within research grants is allowed and encouraged. In addition, EDCTP provides a range of fellowships to early, mid-
career and senior scientists from sub-Saharan. Furthermore, EDCTP has specific fellowships for traineeships in the pharmaceutical industry and regulatory agencies;

- EDCTP supports product development in clinical trials of new pharmaceutical products for poverty-related (HIV, tuberculosis, malaria,) and neglected infectious diseases.
- EDCTP only supports phase I – phase IV clinical studies but does not support basic or pre-clinical research activities. EDCTP only supports maternal and child health clinical studies when it falls under the disease remit of EDCTP (i.e. HIV/AIDS, TB, malaria and neglected infectious diseases that are relevant to sub-Saharan Africa.)
**Fogarty International Center (FIC)**

**Website**  www.fic.nih.gov  
**Contact**  http://www.fic.nih.gov/About/Staff/Pages/default.aspx  

**Funding mission statement**  The Fogarty International Center is dedicated to advancing the mission of the National Institutes of Health (NIH) by supporting and facilitating global health research conducted by U.S. and international investigators, building partnerships between health research institutions in the U.S. and abroad, and training the next generation of scientists to address global health needs.  
http://www.fic.nih.gov/Programs/Pages/default.aspx  

**Potential awardees**  
Academia in US and low to middle income countries  

**Funding basics**  
- Web link to general public funding opportunities  
  http://www.fic.nih.gov/Funding/Pages/Fogarty-Funding-Opps.aspx  
- Web link to previously/currently funded projects  
  http://projectreporter.nih.gov/  

**Research areas supported**  
Basic research  
Translational research  
Operations research  
Epidemiology research  

**Funder Distinctions/Nuances:**  
- FIC primarily supports collaborative international research training grants through solicited applications only.  
- Many of FIC’s programs accept applications in different scientific areas that also include TB.  
  - The **Fogarty HIV Research Training program** will accept applications focused on HIV/TB while the **Global Infectious Disease Research Training Program** will accept TB-related applications.  
  - FIC’s Research Training programs do NOT accept applications from individuals for training but provides support to organizations to establish training programs.  
- FIC does not require co-funding of research projects.
German Federal Ministry for Education and Research (BMBF)

Website www.bmbf.de; www.gesundheitsforschung-bmbf.de
Contact detlef.boecking@dlr.de
Funding mission statement BMBF funds various aspects of R&D. Health research funding follows the Framework Programme for Health Research of the German Federal Government. R&D for poverty associated infectious diseases is funded under the funding concept of the Ministry "Global Health in the Focus of Research (2015)"

Potential awardees
Pharmaceutical industries
Public private partnerships
Private sector
Public sector
Academia

Funding basics
• Web link to general public funding opportunities
• Web link to previously/currently funded projects
http://www.gesundheitsforschung-bmbf.de/de/Gefoerderte%20Projekte.php;
http://foerderportal.bund.de/foekat/jsp/SucheAction.do?actionMode=searchreset
• Time from application to award ranges from 6 to 12 month

Research areas supported
Clinical trials
Lab equipment
Epidemiology
Research training
Pre-clinical development
Pre-clinical services
Product development
Translational research
Basic research
Capacity building in low and middle income countries

Mechanisms to support collaborative projects
Germany is a member of the European and Developing Countries Clinical Trials Partnership (EDCTP), and supports collaborative projects through EDCTP.

Funder Distinctions
• Usual duration of project funding is from 3 to 5 years. There are no restrictions
for repeated applications;
- BMBF funds projects and research institutions;
- Unsolicited grant applications are not accepted. Please note that calls are usually not disease specific but address broader disease spectrums (e.g. infectious diseases, poverty associated diseases, etc.);
- Co-funding of applications is not required for national applications, but international applicants may require co-funding based on the call;
- The funding opportunities are usually for domestic applicants, although calls on PRDs/NTDs are also open to foreign institutions (usually restricted to distinct regions);
- There is no general geographic limitation to applications. Currently the regional focus abroad lies on Sub-Saharan Africa;
- In larger project entities like research networks, there can be resources for individual training;
- Funding is provided for product development;
- Potential applicants can contact the funder in formal terms to discuss the technicalities of the application process.
- DLR project management agency implements and executes the larger part of BMBF's project funding on health research. Please note that there are other project management agencies as well, executing other parts (basic research, support to private pharma research). As mentioned above, BMBF rarely works with calls targeting only one disease. Thus, no specific calls on TB are currently open. Please note also that BMBF funds not only projects but also large research institutions like the German Centre for Infection Research and the Helmholtz-Centre for Infections Research.
German Research Foundation (Deutsche Forschungsgemeinschaft, DFG)

Website  www.dfg.de
Contact  andreas.strecker@dfg.de
Funding mission statement  Funding of excellent basic research in all areas of science in a competitive manner.

Potential awardees
  - Academia
  - Public sector

Funding basics
  - Web link to general public funding opportunities
    http://www.dfg.de/en/research_funding/programmes/index.jsp
  - Web link (if available) to previously/currently Funded Projects
    http://gepris.dfg.de/gepris/OCTOPUS/
  - Time from application to award is 6 months on average.
  - DFG has an open call policy.

Research areas supported
  - Basic research
  - Translational research
  - Clinical trials
  - Epidemiology
  - Research training

Funder distinctions/nuances
  - Funding is normally provided for 2 to 3 years;
  - DFG funds projects only;
  - DFG accepts unsolicited grant applications but exceptions may apply like in the case of the DFG initiative on joint African-German projects in Infectology (http://www.dfg.de/en/research_funding/announcements_proposals/international_context/info_wissenschaft_15_57/index.html);
  - If funding organisations in the partner country exist, co-funding may be required;
  - DFG funds only domestic applicants, funding to partners where no funding possibility exists must be channelled through a German partner (legal obligation).
  - Resources for individual training (for e.g. for students or mentoring for junior investigators etc.) are available;
  - Although applications for product development are generally not funded, transfer of scientific results into pre-stages of product development can be funded;
  - Applicants are welcome to contact DFG to address general questions about the funding process (e.g. technicalities of applying and identification of suitable funding instruments).
National Cancer Institute (NCI)

Website www.cancer.gov
Contact http://www.cancer.gov/global/contact
Funding mission statement The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

Potential awardees (within and outside of the U.S)
   Academia
   Industry
   Public private partnerships
   Patient Advocacy Organizations

Funding basics
   • Web link to general public funding opportunities
     http://www.cancer.gov/researchandfunding
   • Web link to previously/currently funded projects
     http://projectreporter.nih.gov/

Research areas supported
   Basic research
   Translational research
   Clinical trials
   Epidemiology
   Human capital (capacity building)

Funder distinctions/nuances
   • NCI funds projects/organizations, not individual investigators;
   • NCI accepts unsolicited requests for collaboration as well as issues disease-specific calls for proposals;
   • NCI supports training grants for individuals;
   • NCI does not require co-funding of research projects;
   • NCI’s mission focus is cancer, however research that intersects TB related projects with cancer prevention and control could fall within its mission. For instance, NCI supports research on cancer risks and prevention, including smoking prevention and cessation intervention. Because smoking and second-hand smoke exposure is a risk factor for TB as well as cancer, NIC is interested in studies that look at this relationship or test smoking cessation interventions within a TB treatment context.
Every NCATS project is designed to address the “3Ds”: Develop new approaches, technologies, resources and models; demonstrate their usefulness; and proactively disseminate the data, analysis and methodologies so that other scientists can implement them. In this way, NCATS serves as a catalyst, both leveraging others’ work and enabling their work with new technologies, insights and approaches. http://www.ncats.nih.gov/about/faq/faq.html.

Potential awardees (within and outside of the U.S)
   Academia
   Industry
   Public private partnerships
   Patient Advocacy Organizations

Funding basics
   • Web link to general public funding opportunities
   • Web link to previously/currently funded projects
     http://projectreporter.nih.gov/

Research areas supported
   Basic research
   Translational research
   Clinical trials
   Human capital (capacity building)

Funder distinctions/nuances:
   • NCATS funds projects/organizations, not individual investigators;
   • NCATS accepts unsolicited requests for collaboration as well as issues disease-agnostic calls for proposals;
   • NCATS provides resources to support product development;
   • Some NCATS programs offers grant funding while others offer in-kind resource access;
   • Projects may cover the validation of targets and development of probes, assays, chemistry technologies, and novel or repurposed therapeutics related to TB.
National Heart, Lung and Blood Institute (NHLBI)

Website  www.nhlbi.nih.gov
Contact  http://www.nhlbi.nih.gov/about/org/dld/

Funding mission statement  The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. The Division of Lung Diseases (DLD) supports research on the causes, diagnosis, prevention, and treatment of lung diseases and sleep disorders. Research is funded through investigator-initiated and Institute-initiated grant programs and through contract programs in areas including asthma, bronchopulmonary dysplasia, chronic obstructive pulmonary disease, cystic fibrosis, respiratory neurobiology, sleep-disordered breathing, critical care and acute lung injury, developmental biology and pediatric pulmonary diseases, immunologic and fibrotic pulmonary disease, rare lung disorders, pulmonary vascular disease, and pulmonary complications of AIDS and tuberculosis.

Potential awardees (within and outside of the U.S)
- Academia
- Industry
- Public private partnerships

Funding basics
- Web link to general public funding opportunities
  http://www.nhlbi.nih.gov/research/funding/
- Web link to previously/currently funded projects
  http://projectreporter.nih.gov/

Research areas supported
- Basic research
- Translational research
- Clinical trials
- Epidemiology
- Human capital (capacity building)

Funder distinctions/nuances:
- NHLBI funds projects/organizations not individual investigators;
- NHLBI provides resources to support investigator training and also supports the development of tuberculosis curricula for medical schools;
- NHLBI does not require co-funding of research projects;
- TB research is covered by the AIDS/Tuberculosis Program within the Division of Lung Diseases.
Health Research Board

Website www.hrb.ie
Contact hrb@hrb.ie

Funding mission statement  We focus our funding on areas and activities within health research with the greatest potential to bring benefits to people

Potential awardees
Academia
Public sector (clinicians)
NGOs

Funding basics
• Web link to general public funding opportunities  http://www.hrb.ie/research-strategy-funding/open-grants-and-fellowships/
• Web link to previously/currently Funded Projects  http://www.hrb.ie/research-strategy-funding/open-grants-and-fellowships/
• Time from application to award is on average 6-9 months
• TB funding call deadlines are usually in October

Research areas supported
Basic research
Translational research
Product development
Pre-clinical services
Pre-clinical development
Clinical trials
Lab equipment
Epidemiology
Operational research
Research training

Note: HRB’s scope is broad for most funding schemes, and focused schemes are rare. Previous schemes can be accessed here, http://www.hrb.ie/research-strategy-funding/open-grants-and-fellowships/future-calls-schedule/

Funder distinctions/nuances
 o Funding awards for most projects are 3 to 4 years, maximum;
 o HRB funds both investigators and projects;
 o HRB co-funds through applied partnership awards;
 o Lead Applicants must be domestic but international collaborations are encouraged. Funding is predominantly focused on individuals. See http://www.hrb.ie/research-strategy-funding/policies-guidelines-and-grant-conditions/policies-and-position-statements/approval-of-host-institutions/;
 o HRB provides training funds to individuals informs of summer student awards, PhD scholars programmes, early investigator awards, ICE fellowships, etc.;
o Investigator Led Projects can be used to develop interventions. Definitive Intervention and Feasibility Awards can be used to perform feasibility or clinical trial testing on established interventions that need only minor development before implementation;

o Potential applicants can contact HRB to discuss their proposal (there are designated contact persons for each funding call).

o There are mechanisms to support collaborative projects through Clinical Trial Network awards, Definitive Intervention and Feasibility Awards scheme, Investigator Led Projects scheme, and Applied Partnership awards scheme.

o Rolling calls are rare, and random proposals are not accepted. TB research is funded through the Health Professional Fellowships, Health Research Awards (now called Investigator Led Projects), Clinical Scientist Awards, and National SpR/SR Academic Fellowship Programme.
National Health Research Institute, Taiwan

Website  http://www.nhri.org.tw/NHRI_WEB/nhriw001Action.do

Funding mission statement  Scientists at the NHRI conduct mission-oriented medical research and investigate many aspects of basic biomedical sciences, as well as specific diseases.

Potential awardees
  Academia

Funding basics
  • Web link to general public funding opportunities
    https://www.most.gov.tw/
  • Web link to previously/currently funded projects
    https://www.most.gov.tw/
  • Time from application to award is usually 6 months

Research areas supported
  Basic research
  Epidemiology

Funder distinctions/nuances
  • NHRI-Taiwan funds both investigators and/or projects;
  • Both unsolicited grant applications and applications to disease specific calls for proposals are accepted;
  • Co-funding of applications may be required;
  • Only Taiwanese individuals/organizations can apply, and funding is limited to support a BSL 3 animal facility;
  • NHRI-Taiwan provides individual training through MIRU-VNTR and spoligotyping training;
  • NHRI-Taiwan provides resources for product development;
  • There are no mechanisms to support collaborative projects.
National Institute of Allergy and Infectious Diseases (NIAID)

Website  www.niaid.nih.gov
Contact
https://www.niaid.nih.gov/about/respiratory-diseases-branch
https://www.niaid.nih.gov/about/division-aids-contacts
https://www.niaid.nih.gov/about/division-allergy-immunology-transplantation

Funding mission statement  The National Institute of Allergy and Infectious Diseases (NIAID) conducts and supports basic and applied research to better understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases. NIAID is the lead institute within NIH for TB research. In addition, several other Institutes and Centers support R&D activities of relevance to TB Research.

Potential awardees (within and outside of the U.S)
Academia
Industry
Public private partnerships

Funding basics
• Web link to general public funding opportunities
  https://www.niaid.nih.gov/grants-contracts/opportunities
• Web link to previously/currently funded projects  http://projectreporter.nih.gov/

Research areas supported
Basic research
Translational research
Clinical trials
Operations research
Epidemiology
Human capital (capacity building)

Funder distinctions/nuances:
• NIAID offer a wide range of funding and support activities that span basic and clinical research/trials and product development for TB.
• NIAID accepts solicited and unsolicited applications
• NIAID provides funding for specific projects to organizations, training grants are issued to individuals.
• NIAID offers product development assistance through contracts. Some services and resources are offered free of charge to qualified investigators.
• NIAID does not require co-funding of research projects.
• At NIAID, TB research support is provided by several internal Divisions – Division of Microbiology and Infectious Diseases (DMID), Division of AIDS (DAIDS), Division of Allergy, Immunology and Transplantation (DAIT)
• NIAID funding opportunities cover larger infectious disease topics that apply to multiple pathogens. Many funding opportunities are relevant for TB. This includes funding opportunities in HIV that may include projects on HIV/TB co-infections and solicitations for Biodefense/Emerging and Re-emerging Infectious Disease Research (TB is included under Category C).
Research Foundation Flanders (FWO)

Website  www.fwo.be
Contact  med@fwo.be
Funding mission statement  Funding (strategic) basic research in Flanders

Potential awardees
Academia

Funding basics
• Web link to general public funding opportunities
• Web link to previously/currently funded projects
• Time from application to award is on average 6 months

Research areas supported
Basic research
Translational research
Product development
Clinical trials
Clinical development (TBM)

Mechanisms to support collaborative projects
• Research projects
  To support the advancement of fundamental scientific research projects proposed by researchers.
• SBO (Strategic Basic Research) projects
  The Strategic Basic Research (SBO) programme focuses on innovative research, which, if scientifically successful, will create prospects for economic or social applications (e.g. a new generation of products, processes or services).
• TBM (Applied Biomedical Research with a Primary Social finality) projects
  In the long term, the TBM programme aims at contributing to the implementation of new therapies, diagnostic techniques and preventive methods, which, without this government funding, would not make it to the patient due to a lack of industrial interest.

Funder distinctions/nuances
• Funding is usually provided for a maximum period of 4 years per project;
• FWO funds both investigators and/or projects;
• FWO has an open call (non-thematic) policy for all domains of grant application;
• Funding is limited to applicants in Flanders (Belgium);
• Resources are not provided for individual training;
• FWO provides resources for product development;
• Potential applicants are welcome to contact the funders to discuss their proposals
for SBO and TBM research aspects.

- Although FWO has no disease-specific thematic programmes, it can fund TB research if an applicant submits a proposal in the panel covering, among other topics, TB disease.
Swedish Research Council

Website  www.vr.se

Funding mission statement  The Swedish Research Council has a leading role in developing Swedish research of the highest scientific quality

Potential awardees
  Academia

Funding basics
  • Web link to general public funding opportunities
    http://www.vr.se/inenglish/researchfunding/applyforgrants/callforproposals/closedgrants/researchprojectgrantmh.5.26af16d215268a25977388.html
  • Web link to previously/currently Funded Projects
    http://www.vr.se/inenglish/researchfunding/fundinggranted/medicineandhealth.4.3c90cb53157d272286da2da.html
  • Time from application to award is six months
  • The next TB funding call deadline is March 2017

Research areas supported
  Basic research
  Translational research
  Pre-clinical development
  Research training

Funder distinctions/nuances
  • Funding calls are through specific calls every year (no unsolicited application), for a maximum duration of 4 years;
  • The Swedish Research Council funds both projects and/or individuals
  • Co-funding of applications is not required;
  • Only domestic individuals/organizations can apply;
  • Training funds are provided through calls for post docs;
  • There are no resources for product development.
The Netherlands Organisation for Health Research and Development (ZonMw)

Website www.zonmw.nl
Contact Infectiousdisease@zonmw.nl

Funding mission statement  The Netherlands Organisation for Health Research and Development (ZonMw) funds health research and stimulates use of the knowledge developed to help improve health and healthcare in the Netherlands.
http://www.zonmw.nl/en/about-zonmw/what-is-zonmw/

Potential awardees
Academia
Public sector
Public private partnerships
NGOs

Funding basics
• Web link to general public funding opportunities
  http://www.zonmw.nl/en/about-zonmw/
• Web link to previously/currently funded projects
  http://www.zonmw.nl/nl/programmas/programma-detail/infectieziektebestrijding/algemeen/
• Time from application to award is 9 months
• TB funding call opens at the beginning of the year

Research areas supported
Lab equipment
Epidemiology
Operational research
Research training

Funder distinctions/nuances
• Funding durations are for a maximum of 4 years;
• Funding is for projects only;
• Funding applications are only accepted through calls for proposals;
• Co-funding of applications is not required but preferred;
• Combination of national main applicant with international experts in the project group is permitted, but main applicants are required to be based in the Netherlands;
• A training component is funded when encompassed in larger project funding envelopes;
• There is no support for product development within this programme;
• Contacting the funder is allowed for advice on the themes in the call and on individual projects with regard to suitability within the call.
Thrasher Research Fund

Website  www.thrasherresearch.org
Contact  Allison Martinez
Funding mission statement  Thrasher awards grants for research that offers substantial promise for meaningful advances in prevention and treatment of children's diseases.

Potential awardees
    Academia
    Public sector
    NGOs

Funding basics
    • Web link to general public funding opportunities
      www.thrasherresearch.org
    • Web link to previously/currently funded projects
      www.thrasherresearch.org
    • Time from application to award is typically 6 months and funding decisions are typically made in March and September of each year.

Research areas supported
    Translational research
    Clinical trials

Funder distinctions/nuances
    • Funding duration is for up to a maximum of 3 years duration;
    • Thrasher funds projects only;
    • Grant application is through unsolicited grant applications that start with a concept paper (LOI);
    • Co-funding of applications is not a requirement;
    • Funding is not limited to applicants or projects in specific geographic areas;
    • Although funding for training is not available specifically, support to junior personnel can be included as part of a larger project application;
    • Funding is not provided for product development;
    • Potential applicants are welcome to contact the funder to discuss their proposals.
    • Childhood TB is one the areas funded, together with other child diseases and health problems.
United States Agency for International Development (USAID)

**Website**  www.usaid.gov

**Contact**  http://www.usaid.gov/partnerships

**Funding mission statement**  We partner to end extreme poverty and to promote resilient, democratic societies while advancing our security and prosperity

**Potential awardees**
- Academia
- Public sector
- Private sector
- Public private partnerships
- NGOs

**Funding basics**
- Web link to general public funding opportunities

**Research areas supported**
- Translational research
- Product development
- Clinical trials
- Epidemiology
- Operational research

**Funder distinctions/nuances**
- USAID funds both projects and/or individuals;
- Both unsolicited grant applications and disease specific calls are accepted. Check the web site to get more information about rules and regulations associated with submitting unsolicited proposal and how to respond to calls for proposals;
- Co-funding of applications may be required for some calls;
- Both domestic or foreign applicants that are registered to do business with the US federal government can apply;
- Geographic scope of funding opportunities is specified in the call for proposal;
- There are possibilities for funding training but this will vary.
Wellcome Trust

Website: https://wellcome.ac.uk
Contact: Dr Matthew Thakur, m.thakur@wellcome.ac.uk
Funding mission statement: Wellcome exists to improve health for everyone by helping great ideas to thrive.

Potential awardees:
- Pharmaceutical industries
- NGOs
- Public private partnerships
- Private sector
- Public sector
- Academia
- Media sector

Funding basics:
- Web link to general public funding opportunities
  https://wellcome.ac.uk/
- Web link to previously/currently Funded Projects
  https://wellcome.ac.uk/funding/managing-grant/grants-awarded
- TB funding call deadlines, as well as time from application to award vary: please check website.

Research areas supported:
- Pre-clinical development
- Clinical trials
- Lab equipment
- Epidemiology
- Operational research
- Research training
- Pre-clinical services
- Product development
- Translational research
- Basic research
- Social sciences, public engagement/media

Mechanisms to support collaborative projects:

Collaborative awards promote the development of new ideas and speed the pace of discovery. We fund teams of researchers, consisting of independent research groups, to work together on the most important scientific problems that can only be solved through collaborative efforts.

https://wellcome.ac.uk/funding/collaborative-awards-science
Funder distinctions/nuances

- Duration and frequency of funding varies;
- Wellcome Trust funds both projects and/or individuals;
- Grant applications are rarely disease-specific at the moment. Wellcome Trust has open funding calls, but applicants are still expected to be in contact in advance of submitting a large application (for example, teams who put together successful collaborative award applications tend to have had a lot of contact with DFID advisors before submitting their application);
- In some schemes, co-funding may be required;
- Funding may be specific to domestic or foreign applicants based on the call;
- A resource for individual training is available in forms of PhD/MSc programmes. Training can also be encompassed within larger project funding envelopes. For more information, please visit: https://wellcome.ac.uk/what-we-do/teams/innovations-team;
- Potential applicants are encouraged to contact the funder to discuss their proposals;
- Wellcome Trust is sometimes perceived as a more basic science research funder. However, the organization encourages applications from other disciplines like population health. Since there are so many different funding mechanisms, applicants are encouraged to contact the organization via the website so they can be directed through the right route.